



April 8, 2024

RE: Anti-Migraine Medications Coverage Changes Effective April 22, 2024

The following changes will take effect April 22, 2024. Complete prior authorization (PA) criteria can be found on the OHCA website at www.oklahoma.gov/ohca/pa. Pharmacy prior authorization forms can be found on the OHCA website at <https://oklahoma.gov/ohca/rxforms>.

Anti-Migraine Medications

Changes to the Anti-Migraine tier chart include the following:

- Migranal® (dihydroergotamine nasal spray) will no longer be brand preferred. Members currently utilizing brand Migranal® will need to submit a PA request to switch to generic dihydroergotamine nasal spray.
- Zomig® nasal spray (zolmitriptan) will no longer be brand preferred and will be moved to the Special PA Tier. Members currently utilizing brand Zomig® nasal spray will need to switch to a lower-tiered triptan medication.
- Sumatriptan/naproxen will be moved to Tier-3. The individual products are available without a PA. Members currently utilizing sumatriptan/naproxen will need to switch to a lower-tiered triptan medication or submit a PA request for consideration of continuation of therapy.
- Naratriptan will be moved to Tier-1.
- Zolmitriptan tablets and orally disintegrating tablets (ODT) will be moved to Tier-1.

The specific PA requirements and tier chart for the Anti-Migraine Medications are located on the OHCA website at www.oklahoma.gov/ohca/pa in the “Central Nervous System/Behavioral Health” therapeutic category.

Thank you for the services you provide to Oklahomans insured by
SoonerCare!

SOONERCARE PHARMACY SERVICES • PHARMACY MANAGEMENT CONSULTANTS



ADDRESS

4345 N. Lincoln Blvd.
Oklahoma City, OK 73105



WEBSITES

oklahoma.gov/ohca
mysoonerCare.org



PHONE

Admin: 405-522-7300
Helpline: 800-987-7767